Theramex makes a further step towards the consolidation of the fertility footprint by adding Ganirelix Acetate 0.25 mg/ 0.5 mL solution for injection in pre-filled syringe to the existing fertility portfolio

FOR MEDIA AND INVESTORS ONLY

LONDON, UK – November 2021 – Theramex, a global company specialised in women’s health, announced that it has received Decentralised procedure (DCP) approval for Ganirelix Acetate 0.25 mg/ 0.5 mL solution for injection in pre-filled syringe in Portugal, Germany and France. Marketing authorisations for Germany and Portugal are expected by the end of the year, with France having already received its marketing authorization.

Further DCP or National Applications are being submitted in Europe and other countries worldwide.

Gavin Jelic-Masterton, Theramex President of the Global Fertility Franchise, said, “This is a significant day for the Fertility Franchise at Theramex. It clearly demonstrates our commitment to building a first-class portfolio of products giving IVF physicians, and patients, much needed increased choice.”

Robert Stewart, CEO at Theramex says, “Helping women to build families is critical to the role of Theramex and I am delighted to add Ganirelix to our growing Fertility Franchise.”

Theramex acquired rights to Ganirelix in these markets from GP Pharm, a private Spanish biopharmaceutical firm, committed to bringing science to society

Dr. Antonio Parente, President Executive of GP Pharm says “We are very excited about the collaboration with Theramex due to their solid position in the fertility field and we believe that it will be a successful partnership. This collaboration will allow us to continue building on our corporate vision of making injectable products available worldwide”.